Professor Jian Li’s antimicrobial research, clinical translation and commercialisation have provided impactful solutions to combat life-threatening multidrug-resistant bacterial infections globally. Notably, his world-leading research has led to a novel antibiotic drug QPX9003 which was developed intelligently from proof-of-concept to Phase-I trials. Furthermore, his long-term polymyxin pharmacology research has significantly improved clinical practice worldwide. He is a fellow of the American Academy of Microbiology, a Clarivate Highly Cited Researcher, President of the International Society of Anti-infective Pharmacology, and holds multiple other leadership positions in key international societies. Overall, Professor Li has significantly improved the science of antibiotics and human health globally.